Bibliography
- Murphy PM, Charo IF, Hills R, Chemokine receptors, introductory chapter. Last Last modified on 13/10/2009. IUPHAR database (IUPHAR-DB) Available from: http://www.iuphar-db.org/DATABASE/FamilyIntroduction Forward?familyId=14 [Accessed 1 August 2012]
- Busch-Peterson J, Wang Y. Phenol-containing antagonists of the CXCR2 receptor. Expert Opin Ther Patents 2008;18(6):629-37
- Pease JE, Horuk R. Chemokine receptor antagonists: part 2. Expert Opin Ther Patents 2009;19(2):199-221
- Chung KF. Inflammatory mediators in chronic obstructive pulmonary disease. Curr Drug Targets Inflamm Allergy 2005;4(6):619-25
- Kim V, Rogers TJ, Criner GJ. New concepts in the pathobiology of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008;5(4):478-85
- White JR, Lee JM, Young PR, Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J Biol Chem 1998;273(17):10095-8
- SmithKline Beecham Corp. IL-8 Receptor Antagonists. WO1996025157; 1996
- Chapman RW, Phillips JE, Hipkin RW, CXCR2 antagonists for the treatment of pulmonary disease. Pharmacol Ther 2009;121(1):55-68
- Virtala R, Ekman AK, Jansson L, Airway inflammation evaluated in a human nasal lipopolysaccharide challenge model by investigating the effect of a CXCR2 inhibitor. Clin Exp Allergy 2012;42(4):590-6
- Lazaar AL, Sweeney LE, MacDonald AJ, SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans. Br J Clin Pharmacol 2011;72(2):282-93
- Nair P, Gaga M, Zervas E, Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial. Clin Exp Allergy 2012;42(7):1097-103
- Nicholls DJ, Tomkinson NP, Wiley KE, Identification of a putative intracellular allosteric antagonist binding-site in the CXC chemokine receptors 1 and 2. Mol Pharmacol 2008;74(5):1193-202
- Salchow K, Bond ME, Evans SC, A common intracellular allosteric binding site for antagonists of the CXCR2 receptor. Br J Pharmacol 2010;159(7):1429-39
- de Kruijf P, Lim HD, Roumen L, Identification of a novel allosteric binding site in the CXCR2 chemokine receptor. Mol Pharmacol 2011;80(6):1108-18
- Bertini R, Barcelos LS, Beccari AR, Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 non-competitive allosteric inhibitor. Br J Pharmacol 2012;165(2):436-54
- NCT01233232 A 4 Week Study to Investigate the Safety and Tolerability of AZD5069 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (CIRRUS). Available from: http://www.clinicaltrial.gov/ct2/show/NCT01233232
- NCT01255592 Evaluation of the Effect of AZD5069 in Patients With Bronchiectasis (STRATUS). Available from: http://clinicaltrials.gov/ct2/show/NCT01255592
- AstraZeneca AB, AstraZeneca UK Ltd. New crystalline forms of N-[2-[[(2,3-difluoropheny)methyl)thio]-6-{[(1R,2S)-2,3-dihydroxy-1-methylpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfonamide. WO2012007748; 2012
- AstraZeneca AB, AstraZeneca UK Ltd. Pyrimidine sulphonamide derivatives as chemokine receptor modulators. WO2006024823; 2006
- Walters I, Austin C, Austin R, Evaluation of a series of bicyclic CXCR2 antagonists. Bioorg Med Chem Lett 2008;18(2):798-803
- AstraZeneca AB, AstraZeneca UK Ltd. Pyrimidyl sulphone amide derivatives as chemokine receptor modulators. WO2004011443; 2004
- AstraZeneca AB, AstraZeneca UK Ltd. Pyrimidyl sulfonaminde derivative and its use for the treatment of chemokine mediated diseases. WO2010007427; 2010